GA-LDV: A Promising Derivative of 18β-Glycyrrhetinic Acid with Enhanced in vitro and in vivo Anti-Cancer Properties
The newly synthesized GA-LDV derivative demonstrates superior water solubility and significantly enhanced anti-tumor and anti-metastatic activities. The in vitro and in vivo studies indicate that GA-LDV is a promising candidate for further development as a cancer therapeutic agent, with the benefit of potentially reduced systemic toxicity.
Authors
- Qiqi Feng
- Qi Gao (ORCID: https://orcid.org/0000-0002-8068-7599)
- Jiaying Zheng (ORCID: https://orcid.org/0000-0002-7457-6198)
- Xiao–Yi Zhang (ORCID: https://orcid.org/0000-0001-7414-8057)
- Ming Zhao (ORCID: https://orcid.org/0000-0003-0709-8971)
- Yaonan Wang (ORCID: https://orcid.org/0000-0003-2159-2730)
- Shurui Zhao (ORCID: https://orcid.org/0000-0002-0822-3140)
Institutions
- Capital Medical University (CN)
- Beijing University of Chemical Technology (CN)
Publication Details
- Journal
- Drug Design Development and Therapy
- Published
- 2025-04-01
- DOI
- https://doi.org/10.2147/dddt.s492303
- Citations
- 1
- Primary Topic
- Pharmacological Effects of Natural Compounds
- Type
- article
- Field-Weighted Citation Impact
- 1.56
Funders
- National Natural Science Foundation of China